Payment overview · 2025
General Payments
$2,242.95
48 reported records · 14 companies
Healthcare provider profile · identity verified
Alejandro Esteban Gil, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · LOS ANGELES, CA · NPI 1417951963
Verified facts
What the public records show
CMS Open Payments records show Alejandro Esteban Gil, M.D. received $2,242.95 in general payments during 2025 across 48 reported records.
Amgen Inc. accounted for 21.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Entresto, Gemtesa, Jardiance, Kerendia, Linzess, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Lumigan by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Prolia by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 147 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 164 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Synjardy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 164 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 167 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Nuedexta by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $482.23 | 21.5% | 7 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $480.14 | 21.4% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $347.23 | 15.5% | 6 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $248.76 | 11.1% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $167.33 | 7.5% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $147.56 | 6.6% | 6 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $121.96 | 5.4% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $56.21 | 2.5% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $50.31 | 2.2% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $33.99 | 1.5% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $32.90 | 1.5% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $32.25 | 1.4% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $23.29 | 1.0% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.79 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,242.95 | 48 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $480.14 | 9 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $292.96 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $259.66 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $248.76 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $189.27 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $180.46 | 8 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $166.59 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $144.11 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $121.96 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $73.53 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $72.68 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $56.21 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $55.64 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $33.99 | 2 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $32.25 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $32.25 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $23.44 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $23.29 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $18.79 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ENTRESTO entresto |
2025 | Entresto | 2024 | 167 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 38 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 164 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 147 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 127 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 37 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
127 | 29 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
147 | 34 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
164 | 41 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
164 | 41 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
37 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
60 | 17 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
167 | 26 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
38 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 602 | 155 |
| Pioglitazone Hcl | Pioglitazone Hcl | 320 | 76 |
| Tamsulosin Hcl | Tamsulosin Hcl | 271 | 53 |
| Levothyroxine Sodium | Levothyroxine Sodium | 266 | 65 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 230 | 65 |
| Finasteride | Finasteride | 228 | 58 |
| Atorvastatin Calcium | Atorvastatin Calcium | 213 | 53 |
| Metformin Hcl | Metformin Hcl | 199 | 58 |
| Diclofenac Sodium | Diclofenac Sodium | 176 | 53 |
| Metoprolol Succinate | Metoprolol Succinate | 170 | 47 |
| Losartan Potassium | Losartan Potassium | 168 | 41 |
| Entresto | Sacubitril/Valsartan | 167 | 26 |
| Furosemide | Furosemide | 164 | 31 |
| Jardiance | Empagliflozin | 164 | 41 |
| Amlodipine Besylate | Amlodipine Besylate | 163 | 34 |
| Kerendia | Finerenone | 147 | 34 |
| Pantoprazole Sodium | Pantoprazole Sodium | 143 | 39 |
| Clopidogrel | Clopidogrel Bisulfate | 137 | 25 |
| Linzess | Linaclotide | 127 | 29 |
| Potassium Chloride | Potassium Chloride | 125 | 29 |
| Ezetimibe | Ezetimibe | 123 | 28 |
| Omeprazole | Omeprazole | 114 | 30 |
| Clonidine | Clonidine | 111 | 18 |
| Bumetanide | Bumetanide | 109 | 19 |
| Mirtazapine | Mirtazapine | 109 | 20 |
| Eliquis | Apixaban | 108 | 23 |
| Nebivolol Hcl | Nebivolol Hcl | 107 | 20 |
| Vascepa | Icosapent Ethyl | 105 | 23 |
| Benazepril Hcl | Benazepril Hcl | 102 | 30 |
| Montelukast Sodium | Montelukast Sodium | 98 | 27 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 98 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 97 | 33 |
| Azithromycin | Azithromycin | 96 | 62 |
| Atenolol | Atenolol | 91 | 24 |
| Meloxicam | Meloxicam | 91 | 26 |
| Lisinopril | Lisinopril | 87 | 23 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 86 | 17 |
| Cilostazol | Cilostazol | 85 | 18 |
| Valsartan | Valsartan | 85 | 28 |
| Carvedilol | Carvedilol | 83 | 17 |
| Lansoprazole | Lansoprazole | 82 | 20 |
| Azelastine Hcl | Azelastine Hcl | 80 | 35 |
| Glimepiride | Glimepiride | 80 | 18 |
| Hydrocortisone | Hydrocortisone | 77 | 20 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 75 | 18 |
| Icosapent Ethyl | Icosapent Ethyl | 73 | 29 |
| Dexlansoprazole Dr | Dexlansoprazole | 67 | 15 |
| Diltiazem Hcl | Diltiazem Hcl | 67 | 15 |
| Trulicity | Dulaglutide | 60 | 17 |
| Ibuprofen | Ibuprofen | 56 | 12 |
| Sertraline Hcl | Sertraline Hcl | 56 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 56 | 17 |
| Jentadueto | Linagliptin/Metformin Hcl | 54 | 16 |
| Nystatin | Nystatin | 54 | 22 |
| Simvastatin | Simvastatin | 54 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 53 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 52 | 41 |
| Celecoxib | Celecoxib | 51 | 19 |
| Telmisartan | Telmisartan | 51 | 11 |
| Meclizine Hcl | Meclizine Hcl | 48 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 47 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 47 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 46 | 35 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 46 | suppressed |
| Xarelto | Rivaroxaban | 46 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 45 | 11 |
| Farxiga | Dapagliflozin Propanediol | 44 | 21 |
| Alendronate Sodium | Alendronate Sodium | 43 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 43 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 43 | 17 |
| Tradjenta | Linagliptin | 43 | 14 |
| Metoclopramide Hcl | Metoclopramide Hcl | 42 | 15 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 42 | suppressed |
| Januvia | Sitagliptin Phosphate | 41 | suppressed |
| Jentadueto Xr | Linagliptin/Metformin Hcl | 41 | 15 |
| Amiodarone Hcl | Amiodarone Hcl | 40 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 40 | suppressed |
| Sucralfate | Sucralfate | 40 | 13 |
| Gemtesa | Vibegron | 38 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 38 | suppressed |
| Ozempic | Semaglutide | 38 | suppressed |
| Mounjaro | Tirzepatide | 37 | 11 |
| Aliskiren | Aliskiren Hemifumarate | 35 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 35 | suppressed |
| Colchicine | Colchicine | 35 | 11 |
| Primidone | Primidone | 35 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 35 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 33 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 32 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 31 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 31 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 30 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 29 | 14 |
| Alcohol Pads | Alcohol Antiseptic Pads | 28 | suppressed |
| Cefdinir | Cefdinir | 28 | 25 |
| Doxazosin Mesylate | Doxazosin Mesylate | 28 | suppressed |
| Rivastigmine | Rivastigmine | 28 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | suppressed |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Fluconazole | Fluconazole | 25 | suppressed |
| Methotrexate | Methotrexate Sodium | 25 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 25 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 24 | suppressed |
| Nitroglycerin | Nitroglycerin | 24 | 13 |
| Synjardy | Empagliflozin/Metformin Hcl | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 19 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Loperamide | Loperamide Hcl | 23 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 23 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 22 | suppressed |
| Levofloxacin | Levofloxacin | 22 | 19 |
| Midodrine Hcl | Midodrine Hcl | 22 | suppressed |
| Digoxin | Digoxin | 21 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 21 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Cephalexin | Cephalexin | 20 | 15 |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Metolazone | Metolazone | 19 | suppressed |
| Procto-Med Hc | Hydrocortisone | 19 | suppressed |
| Allopurinol | Allopurinol | 18 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 18 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Tadalafil | Tadalafil | 18 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 18 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 17 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Bystolic | Nebivolol Hcl | 16 | suppressed |
| Clotrimazole | Clotrimazole | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Famotidine | Famotidine | 16 | suppressed |
| Fluocinonide | Fluocinonide | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Acamprosate Calcium | Acamprosate Calcium | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Brilinta | Ticagrelor | 15 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Minoxidil | Minoxidil | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 15 | 12 |
| Flucytosine | Flucytosine | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | 12 |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 14 | suppressed |
| Tavaborole | Tavaborole | 14 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 13 | suppressed |
| Edarbi | Azilsartan Medoxomil | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Diclofenac Epolamine | Diclofenac Epolamine | 12 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 12 | suppressed |
| Lumigan | Bimatoprost | 12 | suppressed |
| Mesalamine | Mesalamine | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Prolia | Denosumab | 12 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Mesalamine Er | Mesalamine | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Repaglinide | Repaglinide | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Ssd | Silver Sulfadiazine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,242.95 · 48 records | Amgen Inc. | Auvelity, CAPLYTA, ENTRESTO, EVENITY, GEMTESA, IBSRELA, JARDIANCE, Kerendia, LEQVIO, LINZESS, MOUNJARO, OTEZLA, QULIPTA, REPATHA, REXULTI, UBRELVY, Wegovy, ZEPBOUND, ZORYVE | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Entresto play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error